Eloxx Pharmaceuticals Inc

-0.01 (-2.94%)
Earnings Announcements

Eloxx Pharmaceuticals Reports Fourth Quarter Results

Published: 03/31/2022 12:25 GMT
Eloxx Pharmaceuticals Inc (ELOX) - Eloxx Pharmaceuticals Inc - As of December 31, 2021, We Had Cash and Cash Equivalents of $42.3 Million.
Eloxx Pharmaceuticals- Cash and Cash Equivalents Combined With $7.0 Million From Cf Foundation, Expect Will Be Sufficient to Fund Operations Into Q2 2023.
Eloxx Pharmaceuticals Inc - for Three Months Ended December 31, 2021, Incurred a Net Loss of $12.1 Million, Or $0.14 per Share.
Revenue is expected to be $2.33 Million
Adjusted EPS is expected to be -$0.12

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.12

More details on our Analysts Page.